 <h1>Verteporfin Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to verteporfin: powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, verteporfin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking verteporfin:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision or other change in vision</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Decrease in vision, may be severe</li>
<li> dizziness</li>
<li>dull nervousness</li>
<li> eye pain</li>
<li>fainting</li>
<li>fast, slow, or irregular heartbeat</li>
<li>itching, redness, or other irritation of eye</li>
<li>pale skin</li>
<li>pounding in the ears</li>
<li>troubled breathing on exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of verteporfin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, infection, itching, numbness, pain, rash, redness, scarring, stinging, swelling, tenderness, tingling, ulceration, and/or warmth at the injection site</li>
<li>headache</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Back pain (during infusion of verteporfin)</li>
<li> chills</li>
<li>cloudy urine</li>
<li>constipation </li>
<li>cough</li>
<li>decreased hearing </li>
<li>decreased sensitivity to touch</li>
<li> diarrhea</li>
<li>difficult or painful urination</li>
<li>difficulty in moving</li>
<li>double vision </li>
<li>dry eyes</li>
<li>feeling of constant movement of self or surroundings</li>
<li>fever</li>
<li>general feeling of discomfort or illness</li>
<li> hoarseness</li>
<li>increased sensitivity of skin to sunlight </li>
<li>joint pain</li>
<li>light headedness </li>
<li>loss of appetite</li>
<li>loss of strength or energy</li>
<li>muscle pain or stiffness</li>
<li>nausea</li>
<li>pain, swelling, or redness in joints</li>
<li>pelvic discomfort</li>
<li> redness or other discoloration of skin</li>
<li>runny nose </li>
<li>severe sunburn</li>
<li>shivering </li>
<li>skin rash</li>
<li>sore throat </li>
<li>sweating</li>
<li>tearing</li>
<li>tender, swollen glands in neck</li>
<li>throat congestion</li>
<li>trouble in sleeping</li>
<li> trouble in swallowing</li>
<li>trouble sleeping</li>
<li>varicose veins</li>
<li>voice changes</li>
<li>vomiting</li>
</ul><p>
<!-- end powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to verteporfin: intravenous powder for injection</i></p><h3>Ocular</h3><p>Severe vision decrease, equivalent of more than 4 lines, within 7 days after treatment has been reported in 1% to 5% of patients.  Partial recovery of vision was observed in some patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Cataract (up to 20%)</p>
<p><b>Common</b> (1% to 10%): Visual impairment (e.g., blurry, hazy, fuzzy vision, flashes of light), visual acuity reduced, visual field defect (grey or dark haloes, scotoma, black spots), blepharitis, cataract in the untreated eye, dry eye, severe vision decrease with or without subretinal/retinal or vitreous hemorrhage, diplopia conjunctivitis/conjunctival injection, ocular itching </p>
<p><b>Uncommon</b> (0.1% to 1%): Retinal detachment, retinal hemorrhage, vitreous hemorrhage, retinal edema</p>
<p><b>Rare</b> (less than 0.1%): Retinal ischemia (retinal or choroidal vessel nonperfusion) </p>
<p><b>Frequency not reported</b>: Retinal pigment epithelial tear, macular edema<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site edema, injection site inflammation, injection site extravasation, injection site pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Injection site hemorrhage, injection site discoloration, injection site hypersensitivity</p>
<p><b>Frequency not reported</b>: Injection site vesicles, injection site necrosis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest pain, atrial fibrillation, peripheral vascular disorder, varicose veins</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypertension</p>
<p><b>Frequency not reported</b>: Irregular heart rate, blood pressure fluctuation, flushing, myocardial infarction<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Photosensitivity reaction, pruritus, skin disorder, eczema</p>
<p><b>Uncommon</b> (0.1% to 1%): Rash, urticaria</p>
<p><b>Frequency not reported</b>: Hyperhidrosis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, constipation, GI cancer</p>
<p><b>Frequency not reported</b>: Pelvic pain<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Leukopenia, anemia, white blood cell count decreased, white blood cell count increased<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated liver function tests<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthrosis, arthralgia, myasthenia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Syncope, headache, vertigo</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypoesthesia, hyperesthesia</p>
<p><b>Frequency not reported</b>: Presyncope (vasovagal reactions)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Cough, dyspnea, pharyngitis, pneumonia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Prostatic disorder<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia, decreased hearing</p>
<p><b>Uncommon</b> (0.1% to 1%): Pyrexia</p>
<p><b>Rare</b> (0.01% to 0.1%): Malaise<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza syndrome<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypercholesterolemia, albuminuria, creatinine increased<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Sleep disorder<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Visudyne (verteporfin)" Valeant Pharmaceuticals, Costa Mesa, CA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about verteporfin</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Verteporfin Intravenous, Injection &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Visudyne</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Macular Degeneration</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to verteporfin: intravenous powder for injection</i></p><h3>Ocular</h3><p>Severe vision decrease, equivalent of more than 4 lines, within 7 days after treatment has been reported in 1% to 5% of patients.  Partial recovery of vision was observed in some patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Cataract (up to 20%)</p><p><b>Common</b> (1% to 10%): Visual impairment (e.g., blurry, hazy, fuzzy vision, flashes of light), visual acuity reduced, visual field defect (grey or dark haloes, scotoma, black spots), blepharitis, cataract in the untreated eye, dry eye, severe vision decrease with or without subretinal/retinal or vitreous hemorrhage, diplopia conjunctivitis/conjunctival injection, ocular itching </p><p><b>Uncommon</b> (0.1% to 1%): Retinal detachment, retinal hemorrhage, vitreous hemorrhage, retinal edema</p><p><b>Rare</b> (less than 0.1%): Retinal ischemia (retinal or choroidal vessel nonperfusion) </p><p><b>Frequency not reported</b>: Retinal pigment epithelial tear, macular edema<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site edema, injection site inflammation, injection site extravasation, injection site pain</p><p><b>Uncommon</b> (0.1% to 1%): Injection site hemorrhage, injection site discoloration, injection site hypersensitivity</p><p><b>Frequency not reported</b>: Injection site vesicles, injection site necrosis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest pain, atrial fibrillation, peripheral vascular disorder, varicose veins</p><p><b>Uncommon</b> (0.1% to 1%): Hypertension</p><p><b>Frequency not reported</b>: Irregular heart rate, blood pressure fluctuation, flushing, myocardial infarction<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Photosensitivity reaction, pruritus, skin disorder, eczema</p><p><b>Uncommon</b> (0.1% to 1%): Rash, urticaria</p><p><b>Frequency not reported</b>: Hyperhidrosis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, constipation, GI cancer</p><p><b>Frequency not reported</b>: Pelvic pain<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Leukopenia, anemia, white blood cell count decreased, white blood cell count increased<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated liver function tests<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthrosis, arthralgia, myasthenia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Syncope, headache, vertigo</p><p><b>Uncommon</b> (0.1% to 1%): Hypoesthesia, hyperesthesia</p><p><b>Frequency not reported</b>: Presyncope (vasovagal reactions)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Cough, dyspnea, pharyngitis, pneumonia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Prostatic disorder<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia, decreased hearing</p><p><b>Uncommon</b> (0.1% to 1%): Pyrexia</p><p><b>Rare</b> (0.01% to 0.1%): Malaise<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza syndrome<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypercholesterolemia, albuminuria, creatinine increased<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Sleep disorder<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Visudyne (verteporfin)" Valeant Pharmaceuticals, Costa Mesa, CA. </p><h2>More about verteporfin</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Verteporfin Intravenous, Injection &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Macular Degeneration</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>